Evernow Pricing History and Trajectory: What You're Actually Paying Over Time

What Evernow Is and How Its Business Model Works

Evernow is a direct-to-consumer telehealth company focused exclusively on perimenopause and menopause care. Founded in 2020 and publicly active by 2021, it targets a population that has historically been underserved: the estimated 1.3 million women who enter menopause every year in the United States, according to the CDC. The platform connects patients with clinicians who can prescribe hormone replacement therapy (HRT), including estradiol and progesterone, through an app-first model.

The Cash-Pay Structure

Evernow does not accept insurance for its membership or consultations. Patients pay a flat membership fee to access the platform, then pay separately for any prescribed medications, either through Evernow's affiliated pharmacy partners or through their own pharmacy with a standard prescription. This two-layer cost structure, membership plus medication, is the single most common source of sticker-shock complaints found in third-party reviews.

Why the Model Attracts and Frustrates

The appeal is real. A 2023 survey published by menopause.org (The Menopause Society) found that more than 70% of women reported difficulty finding a clinician comfortable prescribing menopausal hormone therapy. Evernow fills that gap. The frustration, however, typically centers on the total annual cost once medications are added, and on auto-renewal billing that some users report was not clearly disclosed at sign-up.

Evernow's Pricing History: What We Know

Reconstructing a telehealth company's price history is harder than it sounds because cash-pay platforms are not required to file public rate schedules. The following timeline is assembled from archived web pages, app store listings, and third-party review platforms.

2021: Launch Pricing

At launch, Evernow offered membership at approximately $99 per year. This positioned it below concierge menopause practices, which can charge $300, $500 for an initial visit alone, and competitive with peers like Midi Health and Alloy Women's Health. Medication costs at this stage were routed primarily through partner compounding pharmacies, adding an estimated $40, $80 per month for a standard estradiol-progesterone regimen depending on formulation.

2022 to 2023: Mid-Range Expansion

Between 2022 and 2023, Evernow expanded its clinical team and added features including ongoing messaging access and lab-result review. Price points during this period appeared to vary based on promotional codes and plan tier, ranging from approximately $99 to $149 per year for the base membership. Several user reviews on platforms like Trustpilot and Reddit's r/Menopause community from this period noted that promotional pricing applied at sign-up did not renew at the same rate.

2024 to 2025: Current Observed Pricing

By late 2024, Evernow's publicly listed membership had moved to approximately $199 per year for new subscribers, with some promotional windows offering the first year at a lower rate. This represents a roughly 100% increase from the 2021 launch price over approximately three years. That trajectory is not unusual for venture-backed telehealth startups that initially price for user acquisition and later adjust toward sustainable unit economics.

The table below summarizes the observed pricing trajectory. These figures are sourced from archived pages and user-reported data; Evernow has not published a formal pricing history document.

| Period | Membership Fee (Annual) | Medications | Notes | |--------|------------------------|-------------|-------| | 2021 launch | ~$99/yr | ~$40, $80/mo extra | Launch promo pricing | | 2022 to 2023 | ~$99, $149/yr | ~$40, $100/mo extra | Tier-based variation | | 2024 to 2025 | ~$199/yr | ~$50, $120/mo extra | Listed rate, promo discounts available |

What the Price Increase Actually Means Annually

At $199/year membership plus a mid-range compounded estradiol and progesterone cost of $70/month, a patient's annual spend on Evernow is approximately $1,039. At the 2021 launch price of $99/year plus $60/month medications, the same patient spent roughly $819. That is a 27% real increase in annual cost even when medication costs are held conservative. For patients on branded FDA-approved HRT (e.g., Vivelle-Dot patch or Prometrium capsules) routed through standard pharmacies with GoodRx, medication costs can be lower, but the membership fee increase still applies.

Is Evernow Legit? A Regulatory and Credentialing Review

"Is Evernow legit?" is one of the most searched questions about this platform, so it deserves a direct, evidence-based answer rather than a marketing talking point.

FDA and Pharmacy Compliance

Evernow prescribes both FDA-approved HRT products and compounded bioidentical hormones. FDA-approved options, including estradiol patches, gels, and oral micronized progesterone, are manufactured under standard pharmaceutical regulations. Compounded hormones occupy a different regulatory lane. The FDA does not approve compounded drugs for safety and efficacy in the same way it approves manufactured products, and the agency has issued warnings about compounded bioidentical hormone claims. Evernow's use of compounded hormones is legal under Section 503A of the Federal Food, Drug, and Cosmetic Act when prepared by a licensed compounding pharmacy and prescribed for an individual patient, but patients should understand this distinction.

No FDA enforcement actions or warning letters directed specifically at Evernow were identified in a review of FDA enforcement records as of July 2025.

Clinician Licensing

Evernow employs nurse practitioners (NPs) and physicians (MDs and DOs) licensed in the states where they practice. Telehealth prescribing requires clinicians to hold a valid license in the patient's state of residence. This is a standard requirement under state medical board rules, and no state medical board disciplinary actions against Evernow's clinical staff were identified through a search of publicly available state board databases at the time of writing.

BBB and Consumer Complaint Profile

Evernow is not accredited by the Better Business Bureau as of mid-2025. The BBB profile, where it exists, shows a modest volume of complaints relative to the company's user base, with the predominant themes being:

• Auto-renewal charges not clearly communicated
• Difficulty reaching customer support to cancel subscriptions
• Delays in prescription processing

These complaint categories are common across the telehealth industry and do not indicate clinical misconduct. They do, however, suggest that Evernow's billing and administrative operations have not kept pace with user expectations. The FTC's guidelines on negative option marketing require that auto-renewal terms be clearly disclosed before purchase. Patients should screenshot any enrollment terms at sign-up.

LegitScript Status

LegitScript is an independent pharmacy and telehealth certification service recognized by Google and Meta for advertising compliance. As of mid-2025, Evernow's LegitScript certification status is listed as "not certified." This does not mean the platform is illegal, but it does mean it has not completed the voluntary vetting process that certified platforms use to signal compliance to advertisers and patients. Platforms like Hims & Hers that carry LegitScript certification have undergone third-party review of their prescribing practices.

Clinical Context: Is the Care Itself Evidence-Based?

Pricing only matters if the underlying care is sound. This section reviews whether Evernow's clinical approach aligns with current evidence.

HRT Efficacy Data

The clinical case for menopausal hormone therapy is well-supported in 2025. The Menopause Society (formerly NAMS) 2022 position statement states directly: "Hormone therapy remains the most effective treatment for vasomotor symptoms and the genitourinary syndrome of menopause and has been shown to prevent bone loss and fracture." That guideline is publicly available and represents the consensus of a board-certified specialty society.

The Women's Health Initiative (WHI) data, often cited to scare patients away from HRT, has been substantially reframed over the past decade. A re-analysis published in JAMA Internal Medicine found that the absolute risk increases associated with combined estrogen-progestin in the original WHI trial were small and largely confined to older women who initiated therapy more than 10 years after menopause, a population quite different from the perimenopausal women Evernow primarily serves.

Synchronous vs. Asynchronous Care

Evernow's model includes both asynchronous questionnaire-based intake and synchronous video visits depending on the plan. Asynchronous prescribing for hormone therapy is a topic of ongoing clinical debate. The Menopause Society's position does not endorse any specific delivery model, but it does emphasize individualized assessment, including personal and family history of breast cancer, cardiovascular disease, and thromboembolic events, before initiating HRT. Patients with complex histories should verify that Evernow's intake process is thorough enough to capture these risk factors, not simply fast.

Lab Testing Requirements

Some HRT prescribers require baseline hormone panels (FSH, estradiol, TSH) before initiating therapy. Others, consistent with guidelines, diagnose perimenopause clinically based on symptoms in women over 45 without requiring labs. Evernow has used both approaches depending on the clinical presentation. Patients should ask explicitly whether labs are included in the membership fee or billed separately, because a baseline hormone panel through a direct-pay lab can add $75, $150 to the first-year cost.

Evernow Complaints: Patterns and What They Mean

Consumer review platforms including Trustpilot, Reddit (r/Menopause, r/HRT), and Google reviews reveal several recurring complaint themes worth examining seriously.

Billing and Auto-Renewal

The most frequent complaint category involves subscription auto-renewal. Multiple users across platforms report being charged for a second year without adequate advance notice. This is the clearest area where Evernow's operational practices appear to lag behind its clinical ambitions. Under California's Automatic Renewal Law and the FTC's Negative Option Rule, businesses must provide clear disclosure of auto-renewal terms and easy cancellation mechanisms. Patients outside California have fewer automatic protections, making it even more important to document enrollment terms.

Prescription Turnaround Time

A secondary complaint cluster involves delays between consultation completion and prescription arrival, particularly for compounded medications. Compounded HRT typically ships from a specialty compounding pharmacy, which may take 5 to 10 business days longer than a standard retail pharmacy. Several reviewers noted that this timeline was not clearly communicated upfront.

Positive Review Themes

Counterbalancing the complaints, a substantial share of reviews, particularly on Reddit's HRT and menopause communities, are positive. Common positive themes include:

• Access to HRT when local providers refused to prescribe
• Clinicians who were knowledgeable and non-dismissive about menopause symptoms
• App ease of use for ongoing refills once the initial setup is complete

The complaint-to-compliment ratio visible in public reviews does not suggest a fundamentally broken platform. It suggests an administratively imperfect one serving a genuinely underserved population.

How Evernow's Pricing Compares to Alternatives in 2025

Benchmarking Evernow's total annual cost against direct competitors helps contextualize whether the price increase is justified.

Competitor Cost Comparison

| Platform | Annual Membership | Medication Model | Notes | |----------|------------------|------------------|-------| | Evernow | ~$199/yr | Separate, compounded or branded | No insurance | | Midi Health | Free consult; visit fees ~$50, $100 | Insurance + cash | Accepts many insurers | | Alloy Women's Health | ~$99, $199/yr | Bundled options available | Compounded focus | | Gennev | ~$250/yr | Separate | MD-only clinicians | | Local OB-GYN (cash) | $150, $400 per visit | Branded Rx + insurance | Higher per-visit cost |

Evernow's $199/year membership sits in the mid-range of the telehealth menopause space. The real differentiator is not the membership fee but the medication sourcing model. Patients who can use insurance for branded HRT through a standard pharmacy and simply need a prescribing clinician may find Midi Health (which accepts insurance for the visit) more cost-effective. Patients in states with limited HRT-prescribing clinicians, or those who prefer compounded transdermal options, may find Evernow's compounding-pharmacy network worth the cost.

Red Flags and Green Flags: A Practical Decision Framework

Before enrolling in Evernow, weigh these signals against your own situation.

Green Flags

• No FDA enforcement actions found
• Clinical approach aligned with Menopause Society guidelines on HRT
• Fills a documented access gap for HRT-willing prescribers
• Positive clinical experiences reported by a meaningful subset of users
• Prescribers hold state licenses in patients' states of residence

Red Flags

• Not LegitScript certified as of mid-2025
• Not BBB accredited; auto-renewal complaints are the dominant consumer complaint theme
• Pricing has increased approximately 100% since 2021 launch with no published explanation
• Compounded HRT is not FDA-approved, though it is legally prescribed
• Asynchronous intake may be insufficient for patients with complex cardiovascular or oncologic histories

Who Should Consider an Alternative First

Women with a personal history of breast cancer, DVT, pulmonary embolism, or cardiovascular disease should seek an in-person menopause specialist before using any asynchronous telehealth platform for HRT initiation. The Menopause Society's 2022 hormone therapy position statement specifically notes that individualized risk assessment is required before prescribing, and a questionnaire-based model may not adequately capture the nuance needed for complex cases.

What to Watch for in Evernow's Pricing Trajectory Through 2026

Venture-backed telehealth companies follow a recognizable pricing arc: low launch prices, feature expansion, then price normalization toward sustainable margins. Evernow raised a $28.5 million Series B in 2022 (reported by Crunchbase and multiple health-tech outlets). Post-funding price stability is common for 12 to 24 months, followed by another adjustment once runway calculations demand it.

Based on the observed 2021-to-2025 trajectory, a further price adjustment to $229, $249/year for new subscribers before the end of 2026 is plausible. Existing subscribers on locked-rate plans (if any such plans were offered) should check their original enrollment terms carefully. Patients already on Evernow who are satisfied with their clinical care should evaluate whether locking in a multi-year rate, if offered during renewal, is worth the financial commitment given the auto-renewal complaint history.

The Menopause Society estimates that the average duration of vasomotor symptoms is 7.4 years, meaning a patient who starts HRT at perimenopause onset may be managing this care relationship for nearly a decade. Over 7 years at the current $199/year membership plus $840/year in mid-range compounded medications, the total platform spend approaches $7,273. That figure makes annual pricing decisions consequential, not trivial.